Targeted Rheumatoid Arthritis Therapy Using a Smart Nitric Oxide-Responsive JAK Inhibition

Area of Science:

• Immunology
• Pharmacology
• Drug Discovery

Background:

• Rheumatoid arthritis (RA) involves chronic synovial inflammation, leading to joint damage.
• Current Janus kinase (JAK) inhibitors like Tofacitinib (Tofa) risk systemic toxicity due to broad immunosuppression.

Purpose of the Study:

• To develop NOR-Tofa, a nitric oxide (NO)-responsive JAK inhibitor conjugate for targeted activation in inflamed joints.
• To evaluate NOR-Tofa's efficacy and safety in preclinical models of RA.

Main Methods:

• Synthesized and structurally characterized NOR-Tofa, confirming NO-responsiveness and JAK inhibition.
• Assessed NOR-Tofa's in vitro effects on JAK-STAT signaling and cytokine expression in LPS-stimulated macrophages.
• Evaluated NOR-Tofa's in vivo therapeutic efficacy and safety in a collagen-induced arthritis (CIA) mouse model.

Main Results:

• NOR-Tofa demonstrated potent JAK inhibition upon NO-mediated activation.
• In vitro, NOR-Tofa suppressed pro-inflammatory cytokine expression.
• In vivo, NOR-Tofa significantly alleviated arthritis symptoms, preserved joint structure, and showed dose-dependent efficacy.
• Pharmacokinetic and toxicity studies revealed reduced systemic exposure and an improved safety profile compared to Tofacitinib.

Conclusions:

• NO-responsive drug activation is a viable strategy for targeted RA treatment.
• NOR-Tofa offers a safer and more selective alternative to conventional JAK inhibitors for managing rheumatoid arthritis.